FTC seeks contempt ruling against Shkreli over alleged drug-industry ban breach

The Federal Trade Commission said Oct. 12, 2026, it and states asked a federal court to hold Martin Shkreli in contempt — meaning punishment for disobeying a court order — for allegedly breaking his lifetime ban from the pharmaceutical industry. The request asks a judge to decide; it is not a ruling he violated the ban.